La vendita allo scoperto per Mustang Bio dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Mustang Bio. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Mustang Bio (NASDAQ:MBIO) Azioni, Report sulle vendite allo scoperto

Mustang Bio

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Mustang Bio Inc

Thursday&#8217;s <a href="https://www.benzinga.com/etfs/specialty-etfs/25/06/45804512/trump-musk-feud-gets-ugly-etfs-exposed-with-tesla-caught-in-the-crossfire">dramatic fight</a> between President Trump and Tesla CEO Elon Musk, his political ally and donor, sent Tesla stock down more than 14%.
This is just the latest episode in a long string of bad news for Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
The stock, which was trading at around $300 per share on Friday, is down 25% for the year but has gained 11% over the past three months. Poor domestic and international sales, as epitomized by Tesla&#8217;s market share in car-mad Germany being down 36% year-to-year, concerns over robot taxi safety after media reports of a fatal car crash involving Tesla's driver-assistance software and Musk's political forays have stacked the deck against the stock.
With Tesla&#8217;s future looking increasingly uncertain, investors looking to benefit from the rise of electric cars are starting to look elsewhere.
Even as EV sales grow, totaling 20% of new car sales in 2024 globally, the maladies holding EVs back are no secret. In 2025, subsidy schemes are winding down across the globe, tariff fears are fueling price hikes that challenge cash-challenged consumers, charging stations remain spotty, and lower oil prices have combined to throttle electric vehicle (EV) adoption.
Tesla&#8217;s woes are just one example of this trend.
It's been a bumpy ride for electric vehicle stocks near the midpoint of 2025, with the KraneShares Electric Vehicles Future Mobility Index benchmark ETF up 2.0% in 2025. The fund, which tracks the Bloomberg Electric Vehicle Index, has been a portfolio drainer for a while now—down over 15% over the past three years.
One saving grace of late is China, where low battery prices, attractive trade-in deals, and a supportive government have helped EV sales rise by 40% in 2024 on a year-to-year basis. By the end of 2024, China accounted for two-thirds of all worldwide EV sales – that's up from half of all sales in 2021, according to the<a href="https://www.iea.org/reports/global-ev-outlook-2025/trends-in-electric-car-markets-2"> International Energy Agency's Global EV Outlook for 2025</a>.
"The EV market will continue to depend upon a mix of subsidies, incentives, and favorable trade policies," said David Nicholson, chief technology advisor at The Futurum Group in San Francisco, Cal. "Against this backdrop, Chinese EV manufacturers will face varying levels of protectionism. That will be the dominant theme moving forward. &#8220;How much will the rest of the world allow China to access its EV consumers?&#8221;
With EV long-term prospects on more solid footing against 2025 share price woes, which electric vehicle stocks resonate in 2025? Here's a snapshot.
<h2 class="wp-block-heading">Wall Street's Elite Are Betting Big on These Stocks</h2>
What's Wall Street buying right now? Benzinga Edge gives you instant access to ratings from 1,000 top analysts. From Goldman Sachs to Morgan Stanley and more—discover which stocks the smart money is piling into…and potentially profit alongside them. Unlock All Wall Street Stock Ratings <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/">HERE</a>
<h2 class="wp-block-heading">Tesla Inc.</h2>
Many of Tesla's current problems are short-term, with tariffs and political skirmishes involving Musk having only so much staying power. That doesn't mean Tesla is in a good spot, particularly with the proposed "Big Beautiful Bill" recently passed by the U.S. House of Representatives, which is looking to clear the Senate in June and appears to have set off the Musk-Trump feud. Among other features, the legislation curbs or, in some cases, outright eliminates EV and green energy tax credits introduced in 2022's Inflation Reduction Act. 
That's not good news for EV giants like Tesla, which count on credits to move vehicles. According to J.P. Morgan analyst Ryan Brinkman, if the tax act is passed with the EV credits neutered, Tesla could cost $2 billion. Brinkman has a sell call on TSLA, with a steep 65% slide in Tesla stock in play the following year.
However, if you have full confidence in Tesla's ability to bring new transport technologies like robot taxis to the market, then Tesla makes sense.
"Tesla&#8217;s value is based more upon future expectations of their ability to deliver in AI and Robotics than it is based on a realistic assessment to grow market share in vehicle sales," Nicholson said. "If you believe in the robotics story in particular, you buy or hold Tesla stock."
<h2 class="wp-block-heading">BYD Co. Ltd.&nbsp;</h2>
BYD (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>), China's leading EV manufacturer, is conducting a cost-cutting campaign amid a slowing Chinese economy, expanded in-country electric vehicle competition, and collapsing EV sales in Europe. These factors are weighing heavily on China's auto manufacturing sector.
Yet BYD continues to dodge the deluge. The stock is up 53.18% year-to-date and up 6% over the past month, as the Shenzhen-based automaker has cut prices on 22 EV and hybrid vehicle models and will continue to do so through the end of June. Speculation is rising that BYD will continue to keep its EV price tags lower as it eventually edges into the US market, which would constitute a big problem for Tesla and major US automakers.
Analysts are backing the stock, with Macquarie holding its Buy Rating on BYD, according to a late May research note, and Erste Group initiating coverage with a Buy.
<h2 class="wp-block-heading">Rivian Automotive Inc.</h2>
Rivian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) has been picking up steam lately, with its stock price up 23% over the past three months, and it has an intriguing story to tell. The EV manufacturer is aiming for the SUV and truck-driving consumer, which can be a tough sell in a downbeat economy. The numbers back that sentiment up, with deliveries down from 51,000 in 2024 to an estimated range of 40,000 to 46,000 in 2025, as high prices keep would-be buyers on the sidelines.
Yet RIVN is making strides in other areas. The company has a big delivery van deal with Amazon and has partnered with Volkswagen in a $5.8 billion software and services deal that helped RIVN net $167 million in the first quarter of 2025.
Revenues were up 3% for the first quarter of 2025 and the company has recorded two straight quarters of gross profit and production on its lower-cost R2 EV model (costs clocked in at $45,000 compared to $76,000 for Rivian's R1 line).
Rivian investors may have to show patience for a company focused on the long haul, but analysts see a big upside. Exhibit A is Exane BNB Paribas' James Picariello, who recently issued a Buy rating on the stock with a $20 price target, up above 40% from where the stock is trading as of writing.
Editorial content from our expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

Opinion

Trading Ideas

BYDDY

RIVN

TSLA

Top 2 Alternatives To Tesla After The Musk-Trump Breakup

We are offering 2,250,000 shares of our common stock (or 2,587,500 shares if the underwriters exercise the overallotment option described below), par value $0.0001 per share (the "common stock"), at a public offering price per share of $8.00.
&nbsp;
Our common stock is listed under the symbol "BMNR" on the NYSE American.
&nbsp;
&nbsp;
The share and per share information in this prospectus, unless otherwise noted and other than in our financial statements and the notes thereto, reflect the reverse stock split of our outstanding shares of common stock at a 1-for-20 ratio pursuant to the filing of a&nbsp;Certificate of Amendment to our Amended and Restated Certificate of Incorporation on May 15, 2025.
&nbsp;

News

Offerings

BMNR

BMNR Announces Public Offering Of 2.25M Shares At $8.00 Each

<a href="https://www.businessinsider.com/amazon-freezes-hiring-budget-retail-business-this-year-2025-6" title="https://www.businessinsider.com/amazon-freezes-hiring-budget-retail-business-this-year-2025-6">https://www.businessinsider.com/amazon-freezes-hiring-budget-retail-business-this-year-2025-6</a>

Management

AMZN

'Amazon Freezes Hiring Budget For Its Big Retail Business This Year' - Business Insider Exclusive

Rubrik, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) shares are trading on volatility Friday. The company repotted better-than-expected first-quarter financial results and issued second-quarter guidance above estimates on Thursday after the <a href="https://www.benzinga.com//node/45802271">market closed.</a>
The Details: Rubrik reported an adjusted loss of 15 cents per share, beating the consensus estimate of a 32 cent-loss. In addition, the company reported sales of $278.48 million, beating the consensus estimate of $260.35 million, and representing a 49% year-over-year growth.
Rubrik announced subscription annual reoccurring revenue grew 38% year-over-year to $1.89 billion.
The company ended the quarter with $762.1 million in cash, cash equivalents and short term investments.
Outlook: The company expects an adjusted loss per share of 33 to 35 cents for the second quarter, versus the 36-cent loss expected by analysts. Furthermore, it anticipates sales from $281 million to $283 million, versus the consensus estimate of $273.59 million.
The company now sees an adjusted loss per share from $1.02 to 96 cents for the fiscal-year, versus the consensus estimate of a $1.15 loss. It previously expected a loss between $1.23 and $1.13.
The company expects sales from $1.18 billion to $1.19 billion, versus the consensus estimate of $1.16 billion. It previously saw sales from $1.15 billion to $1.16 billion.
Analyst Changes: Following the earnings report, multiple analysts <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=http://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45813574/these-analysts-boost-their-forecasts-on-rubrik-after-better-than-expected-q1-results&amp;ved=2ahUKEwjUobnujt2NAxVrmokEHVHfAWUQFnoECCUQAQ&amp;usg=AOvVaw0nTKSuroqaGfjZTQ8f4E2h">issued price target adjustments</a>.
<ul class="wp-block-list">
<li>Guggenheim analyst John Difucci maintained a Buy rating on Rubrik and raised the price target from&nbsp;$105&nbsp;to&nbsp;$108.</li>
<li>Truist Securities analyst Joel Fishbein maintained a Buy rating on Rubrik and raised the price target from&nbsp;$90&nbsp;to&nbsp;$110.</li>
<li>Baird analyst Shrenik Kothari maintained an Outperform rating on Rubrik and raised the price target from&nbsp;$95&nbsp;to&nbsp;$110.</li>
<li>Wells Fargo analyst Andrew Nowinski maintained an Overweight rating on Rubrik and raised the price target from&nbsp;$80&nbsp;to&nbsp;$125.</li>
<li>Cantor Fitzgerald analyst Jonathan Ruykhaver maintained an Overweight rating on Rubrik and raised the price target from&nbsp;$95&nbsp;to&nbsp;$115.</li>
</ul>
See Also: <a href="https://www.benzinga.com/markets/large-cap/25/06/45817251/rio-tinto-opens-2b-pilbara-iron-ore-mine-with-chinas-baowu">Rio Tinto Opens $2B Pilbara Iron Ore Mine With China&#8217;s Baowu</a>
RBRK Price Action: At the time of writing, Rubrik stock is trading 1.02% lower at $97.57, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwjT9p_c_NyNAxWok4kEHbkOLfYQFnoECBEQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>.
Image: via Shutterstock

Movers

RBRK

What's Going On With Rubrik Stock Friday?

Wall Street surged into rally mode during the final trading session of the week as better-than-expected jobs data helped ease fears <a href="https://www.benzinga.com/markets/economic-data/25/06/45818251/trump-cheers-strong-jobs-data-renews-attack-on-feds-powell-rates-should-be-much-lower">of an economic slowdown.</a>
In May, nonfarm payrolls increased by 139,000—a slight dip from April's downwardly revised 147,000, but above economist forecasts of 130,000. The unemployment rate held steady at 4.2%, while wage growth beat expectations, signaling a potential<a href="https://www.benzinga.com/markets/economic-data/25/06/45812372/us-labor-markets-defies-tariff-concerns-as-nonfarm-payrolls-wages-top-expectations-in-may"> boost to consumer spending.</a>
The S&amp;P 500 rose 0.9% nearing the 6,000 mark, its highest level since Feb. 24. The Nasdaq 100 climbed 1% to over 21,720, putting tech stocks within striking distance—just 2 percentage points—of record highs.
In equities, Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rebounded 5.6%, partially recovering from Thursday's 14% plunge triggered by a high-profile clash between Elon Musk and President Donald Trump. Cooler rhetoric on Friday helped sentiment, after the White House said no call between Trump and Musk was currently planned.
Stronger-than-expected economic data also lifted the U.S. dollar and Treasury yields, with the 10-year yield climbing 10 basis points to 4.5%.
Gold dropped 0.9% to $3,321, heading for its worst session of the week. In contrast, crude oil rallied 2.5% to nearly $65 a barrel—its highest since early April—on signs of easing geopolitical risk as Trump and Chinese President Xi Jinping agreed to meet, calming market fears of a renewed tariff war that could dent global energy demand.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) advanced 3.4% to $105,000, nearly erasing Thursday's decline.
Read also: <a href="https://www.benzinga.com/news/politics/25/06/45817556/trump-musk-feud-sends-betting-markets-into-overdrive-heres-what-traders-see-next">Trump-Musk Feud Sends Betting Markets Into Overdrive: Here&#8217;s What Traders See Next</a>
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg (%)</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,126.31</td>
<td>1.4%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,727.92</td>
<td>1.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,993.56</td>
<td>0.9%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,648.75</td>
<td>0.8%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:40 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.8% to $597.90.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.8% to $427.22.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.9% to $529.17.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rallied 1.4% to $211.34.</li>
<li>The&nbsp;Energy&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 2%; the&nbsp;Utilities&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 0.1%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
<ul class="wp-block-list">
<li>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) fell 4% despite slightly beating the Street&#8217;s estimates on both sales and earnings last quarter.</li>
<li>Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) tumbled 20% as strong first-quarter results were overshadowed by a lowered full-year profit outlook, driven by rising tariff costs and increased markdowns.</li>
<li>Other stocks reacting to earnings included DocuSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) down 18.4%, Vail Resorts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) down 3.7%, Samsara Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>), down 4.9% and ABM Industries Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) down 14.5%. </li>
</ul>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/commodities/25/06/45819573/silver-tops-36-triggering-a-generational-technical-breakout">Silver Tops $36, Triggering A Generational Technical Breakout </a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Equities

Government

Large Cap

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Small Cap

Treasuries

Econ #s

Economics

Tech

ETFs

$BTC

AVGO

SPDR Dow Jones Industrial Average ETF Trust

DOCU

LULU

Select Sector SPDR-Consumer Discretionary

Stocks Rally On Strong Jobs Numbers; Tesla Rebounds As Trump-Musk Feud Softens: What's Driving Markets Friday?

Raymond James analyst Sam Darkatsh maintains Toro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTC#NYSE">TTC</a>) with a Outperform and lowers the price target from $95 to $90.

Price Target

Analyst Ratings

Raymond James Maintains Outperform on Toro, Lowers Price Target to $90

Raymond James analyst Brian Peterson maintains Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) with a Outperform and lowers the price target from $48 to $43.

BRZE

Raymond James Maintains Outperform on Braze, Lowers Price Target to $43

Oppenheimer analyst Ittai Kidron maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Outperform and raises the price target from $225 to $250.

SNOW

Oppenheimer Maintains Outperform on Snowflake, Raises Price Target to $250

Federal Reserve

Live On CNBC, Fed's Harker Says Sees Steadiness In 'Solid' Latest Job Data; Much Of Tariff Impacts Yet To Be Felt; Fed Interest Rate Policy Is Modestly Restrictive; Now Is Time For Fed To Hold Steady And Watch Data

Oppenheimer analyst Ittai Kidron maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Outperform and raises the price target from $290 to $345.

Oppenheimer Maintains Outperform on Zscaler, Raises Price Target to $345

BRLS

Borealis Foods Shares Halted On Circuit Breaker To The Downside, Stock Now Up 80%

WIIM

CYCU

Cycurion shares are trading lower after the company reported a Q1 EPS miss.

Oppenheimer analyst Leland Gershell initiates coverage on Climb Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLYM#NASDAQ">CLYM</a>) with a Outperform rating and announces Price Target of $10.

Initiation

CLYM

Oppenheimer Initiates Coverage On Climb Bio with Outperform Rating, Announces Price Target of $10

Insider Trades

Abacus Global Management Form4 Filing Shows President Kevin Scott Kirby Bought 86,207 Shares At An Average Price Of $5.77/Share; President Sean McNealy Bought 86,207 Shares At An Average Price Of $5.77/Share

Oppenheimer analyst Brian Schwartz maintains Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) with a Outperform and lowers the price target from $51 to $44.

Oppenheimer Maintains Outperform on Braze, Lowers Price Target to $44

NVNO

enVVeno Medical shares are trading higher after the company announced its interim two-year follow-up data on the VenoValve trial.

Abacus Global Management Form4 Filing Shows CFO William Hugh McCauley Bought 33,000 Shares At An Average Price Of $5.82/Share

JPMorgan analyst Doug Anmuth reiterated the Overweight rating on Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>),<a href="https://www.benzinga.com/quote/CHWY/analyst-ratings" target="_blank" rel="noreferrer noopener"> with a price target of $36.</a>
The company will report fiscal first quarter 2025 financial results before the market <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45316009/chewy-announces-fiscal-first-quarter-2025-financial-results-conference-call" rel="noreferrer noopener">opens on Wednesday, June 11.</a>
According to Anmuth, investors are anticipating an upside to Chewy's Q1 net sales guidance of $3.06 billion–$3.09 billion and see the company raising its FY25 outlook for net sales of $12.30 billion–$12.45 billion and adjusted EBITDA margins of 5.4%–5.7%.
Anmuth maintains a bullish view on Chewy, citing its category leadership, rising profitability, and push to diversify revenue through high-margin segments like pharmacy (now at $1 billion TTM), international expansion, and Sponsored Ads.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45630622/chwy-stock-short-interest-contrarian-trade" rel="noreferrer noopener">Options Corner: A Contrarian Case Builds As Traders Short Chewy Ahead Of Earnings</a>
He notes Chewy is seen as a defensive name, with over 80% of sales coming from Autoship customers, which he sees as a major edge supporting revenue visibility and strong unit economics.
He forecasts net customer adds of 104K sequentially in the first quarter of FY25 and 421K year over year for the full year.
SimilarWeb shows the company&#8217;s web traffic rose 4% year over year in the first quarter (down from 13% in the fourth quarter), with a pickup in May, while Bloomberg points to improving trends into the second quarter.
He estimates 6% year-over-year net sales growth for the first quarter and 3% for FY25—figures he considers may be conservative.
Anmuth sees profitability supported by ads, mix, automation, scale, and cost control, projecting a 5.4% adjusted EBITDA margin (+59bps year over year) and $524M in FCF (+16% year over year).
Price Action: CHWY shares are trading higher by 1.5% to $48.19 at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45818750/docusign-posts-beat-and-raise-quarter-stock-tanks-almost-20" target="_blank" rel="noreferrer noopener">DocuSign Posts Beat-And-Raise Quarter; Stock Tanks Almost 20%</a></li>
</ul>
Photo: Briana Hunter/Shutterstock

Markets

General

CHWY

Chewy's Loyalty Engine, $1B Pharmacy Business Have JPMorgan Staying Bullish Before Q1

iPower shares are trading higher after the company announced the formation of United Package NV LLC.

<h3>Gainers</h3>
<ul>
<li>Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) stock moved upwards by 44.6% to $1.75 during Friday's regular session. The market value of their outstanding shares is at $186.4 million. </li>
<li>Rent the Runway (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENT#NASDAQ">RENT</a>) stock moved upwards by 31.23% to $8.85. The market value of their outstanding shares is at $35.5 million. The company's, Q1 earnings came out yesterday. </li>
<li>iRobot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) shares moved upwards by 16.56% to $3.9. The company's market cap stands at $119.6 million. </li>
<li>GoPro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPRO#NASDAQ">GPRO</a>) shares moved upwards by 15.87% to $0.8. The market value of their outstanding shares is at $125.2 million. </li>
<li>QuantaSing Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) stock rose 15.74% to $6.47. The company's market cap stands at $330.7 million. The company's, Q3 earnings came out today. </li>
<li>Red Robin Gourmet Burgers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRGB#NASDAQ">RRGB</a>) shares increased by 15.15% to $6.99. The market value of their outstanding shares is at $123.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>YSX Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YSXT#NASDAQ">YSXT</a>) stock fell 29.1% to $5.0 during Friday's regular session. The market value of their outstanding shares is at $117.1 million. </li>
<li>Petco Health and Wellness (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOOF#NASDAQ">WOOF</a>) shares fell 24.89% to $2.72. The company's market cap stands at $758.5 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Jiade (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) shares fell 22.13% to $0.27. The market value of their outstanding shares is at $6.5 million. </li>
<li>Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) stock declined by 20.18% to $264.05. The company's market cap stands at $33.0 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) shares fell 15.08% to $23.5. The market value of their outstanding shares is at $1.0 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Mullen Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) shares decreased by 13.32% to $7.03. The market value of their outstanding shares is at $3.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CHGG

GIII

GPRO

IRBT

JDZG

MULN

RENT

RRGB

WOOF

YSXT

12 Consumer Discretionary Stocks Moving In Friday's Intraday Session

Financing

Press Releases

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

Health Care

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Mustang Bio Receives Positive Listing Determination from Nasdaq

Mustang Bio Announces Reverse Stock Split

IPOs

Mustang Bio Announces Pricing of $8 Million Public Offering

Mustang Bio Announces Closing of $8 Million Public Offering

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

FBIO

MBIO

Apollomics Inc. - Class A Ordinary Shares

Apollomics

180 Life Sciences

Azitra

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Ensysce Biosciences

Galecto

GT Biopharma

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Polyrizon

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Sunshine Biopharma

SILO Pharma

Soligenix

Synaptogenix

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Tharimmune

Theriva Biologics

Xenetic Biosciences

HC Wainwright & Co.

Cantor Fitzgerald

BTIG

Comments

Mustang Bio

Vendite allo scoperto

Mustang Bio (NASDAQ:MBIO) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO